SEC Form 3 · accession 0001104659-15-061393
Cardiff Oncology, Inc. · CRDF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew L. Posard
Officer — Chief Commercial Officer
Period of report
Aug 21, 2015
Accepted (ET)
Aug 24, 2015 · 8:21 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001213037
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 15,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2 | $5.39 | holding | — | — | — | — | Feb 17, 2025 | Common Stock | 500,000 | — | D |
Explanation of responses
- F1Shares were purchased on August 19, 2015 at $5.75 per share.
- F2The Stock Options vest in accordance with the following schedule: 125,000 options vest on each of 3/16/2016, 2017, 2018 and 2019.